Tirzepatide shows the lowest discontinuation rates due to adverse events in clinical trials (4-7%), followed closely by semaglutide (approximately 7%)
Individuals with severe gastrointestinal disorders, such as inflammatory bowel disease or short bowel syndrome, may experience exacerbated symptoms like nausea, vomiting, or diarrhea, requiring careful assessment before use
But the best medication is the one you actually take consistently, month after month, without financial strain or intolerable side effects derailing your progress
This finding has direct implications for how you should structure your calorie intake and macronutrient ratios
Tirzepatide dose-dependently leads to clinically significant reductions in glycemic parameters and body weight and has been shown to have stronger effects in reducing these parameters than standard antidiabetic therapy
Inspect the medication through the pen window to ensure it appears clear and colorless to slightly yellow
